MT-CO1 and Huntington disease: We employed rotenone and 3-nitropropionic acid (3-NP), mitochondrial CoI and CoII inhibitors, respectively, widely used in modeling central facets of the neurodegenerative disorders Parkinson’s disease (PD) and Huntington’s disease (HD), respectively.